Approved & therapeutic
Triptorelin
Trelstar, Triptodur
Triptorelin is a GnRH agonist depot approved for advanced prostate cancer and, in a separate formulation, for central precocious puberty. Depot intervals range from four weeks to six months.
Also known as: Trelstar, Triptodur, triptorelin pamoate, Decapeptyl
- Status
- Triptorelin is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Depot formulations sustain exposure over 4 weeks to 6 months depending on product.
- How it's taken
- Intramuscular depot injection
- Mechanism
- Reproductive axis (GnRH / kisspeptin / oxytocin)
- Pathways
- GnRH, Androgen, Estrogen
How Triptorelin works
Triptorelin produces the same agonist-then-desensitisation sequence as other GnRH agonists: an initial LH and FSH surge, followed within two to four weeks by profound suppression of gonadotropins and sex steroids.
What research has looked at
- Achieves and maintains castrate testosterone in advanced prostate cancer.
- Suppresses the pituitary-gonadal axis in central precocious puberty, with a six-month formulation available.
- Long depot intervals reduce clinic visits relative to monthly dosing.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Initial testosterone surge with the risk of transient disease flare, including bone pain and urinary obstruction in prostate cancer.
- Hot flashes, decreased libido, erectile dysfunction and fatigue.
- Decreased bone mineral density with prolonged androgen deprivation.
- Hyperglycaemia and increased cardiovascular risk with long-term therapy.
- Injection-site reactions and anaphylaxis have been reported.
Sources
- FDA approved-drug listing for triptorelin · U.S. Food & Drug Administration
- DailyMed prescribing information for triptorelin · NIH · DailyMed
- PubMed research on triptorelin depot prostate cancer · NIH · National Library of Medicine
- DrugBank record for triptorelin · DrugBank
Track Triptorelin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Triptorelin FAQ
What is Triptorelin?
Triptorelin is a GnRH agonist depot approved for advanced prostate cancer and, in a separate formulation, for central precocious puberty. Depot intervals range from four weeks to six months.
How does Triptorelin work?
Triptorelin produces the same agonist-then-desensitisation sequence as other GnRH agonists: an initial LH and FSH surge, followed within two to four weeks by profound suppression of gonadotropins and sex steroids.
Is Triptorelin FDA approved?
Yes. Triptorelin is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Triptorelin?
Reported half-life: Depot formulations sustain exposure over 4 weeks to 6 months depending on product.
How is Triptorelin taken?
Intramuscular depot injection.
What side effects have been reported with Triptorelin?
Reported in the sources: Initial testosterone surge with the risk of transient disease flare, including bone pain and urinary obstruction in prostate cancer; Hot flashes, decreased libido, erectile dysfunction and fatigue; Decreased bone mineral density with prolonged androgen deprivation; Hyperglycaemia and increased cardiovascular risk with long-term therapy; Injection-site reactions and anaphylaxis have been reported.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.